Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers, Manali Kamdar, Andrew McMillan, Mark Hertzberg, Sarit Assouline, Tae Min Kim, Won Seog Kim, Muhıt Özcan, Jamie Hirata, Elicia Penuel, Joseph N. Paulson, Ji Cheng, Grace Ku, Matthew J. Matasar

Journal of Clinical Oncology, 2019

Spinal Cord Injury BC, University of British Columbia, City of Hope, Emory University, University of Colorado Anschutz Medical Campus, University of Colorado Denver, Nottingham University Hospitals NHS Trust, Prince of Wales Hospital, Seagen (Canada), Roche (Switzerland), Bayer (United States), Daiichi Sankyo (India), Juno Therapeutics (Germany), GlaxoSmithKline (India), Janssen (Belgium), Pharmacyclics (United States), Jewish General Hospital, Seoul National University Hospital, Samsung Medical Center, Ankara University, Roche (Canada), Memorial Sloan Kettering Cancer Center

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with Journal of Clinical Oncology. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

755

Citations

View on Google Scholar

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Abstract

Journal Details

Join JournalsHub

Welcome Back